• Spectral Medical posted Q2 2026 revenue of CAD 621,000, down 24%.
• Net results swung to a profit of CAD 331,000 from a loss a year earlier, as operating expenses fell 98% to CAD 62,000.
• Cash ended June 30 at CAD 803,000, down from CAD 4.07 million at Dec. 31.
• FDA filed PMX’s PMA application on June 25, moving it into substantive review; 12-month Tigris mortality was 52.8% vs 66.7%.
• Vantive completed a US$2 million Tranche D advance, including a US$1 million payment received July 28, as commercialization planning continued.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070730PRIMZONEFULLFEED9805828) on August 07, 2026, and is solely responsible for the information contained therein.